Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2025 | $4.00 | Buy | Lake Street |
4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
Lake Street initiated coverage of Adagio Medical Holdings with a rating of Buy and set a new price target of $4.00
Marie-Claude Jacques appointed Senior Vice President, Global Sales; Antwan Gipson joins as Senior Vice President, Manufacturing & Operations Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced two key additions to its senior leadership team: Marie-Claude Jacques as Senior Vice President, Global Sales and Antwan Gipson as Senior Vice President, Manufacturing and Operations. "These appointments represent a significant milestone as Adagio prepares for commercialization of our proprietary Ultra-Low Temperature Cardiac Ablation technology ("ULTC") for electrophys
Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Sean Salmon has been appointed to its Board of Directors. Mr. Salmon will also serve on the Company's Audit Committee and Compensation Committee. Mr. Salmon, 60, recently retired from Medtronic after a distinguished, 20+ year tenure during which he held multiple senior global leadership roles across the company's cardiovascular and diabetes businesses. Most recently, he served as Executive Vice President and President of Medtronic's Cardiovascular Portfolio, which includes the Cardiac Rhythm, Cardiac Abl
Continued Momentum Toward PMA Submission of ULTC Technologies Recent Financing Positions Company to Execute Growth Strategy Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025. Recent Business Highlights: Closed a private placement on October 20, 2025, with gross proceeds of up to $50 million, led by a syndicate of healthcare-dedicated institutional investors; upfront proceeds of approximately $19 million expected to fund FDA submission activities and ongoing next generation catheter deve
SCHEDULE 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)
SCHEDULE 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)
SCHEDULE 13G/A - Adagio Medical Holdings, Inc. (0002006986) (Subject)
4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026 at 2:30 PM ET in Boston, MA. Presentation Information A live webcast and replay of the session will be accessible at https://event.summitcast.com or on the Company's website at https://investors.adagiomedical.com. About Adagio Medical Holdings, Inc. Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel,
NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Small Cap Growth Virtual Investor Conference, held February 5th are now available for on-demand viewing. Individual investors, institutional investors, advisors, and analysts are invited to attend.REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through February 10th. Please Schedule 1x1 Meetings here Febru
Early Feasibility Outcomes in a Real-World Patient Cohort of Both Ischemic and Challenging Non-Ischemic Patients Published in Circulation: Arrhythmia and Electrophysiology Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of results from the U.S. Early Feasibility Study ("EFS") evaluating ultralow temperature cardiac ablation ("ULTC") for the treatment of scar-related ventricular tachycardia ("VT"). The study was published in Circulation: Arrythmia and Electrophysiology. The prospective, multi-center study was conducted under the U.S. Food
SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)
SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)